AUSTRALIAN drug development
company Avexa has dropped its
HIV program after it failed to
secure a manufacturer to market its
apricitabine antiviral therapy for the
treatment of drug resistant HIV.
CEO Julian Chick has also
advised that he will assume
responsibility for apricitabine’s
commercial failure by stepping
down from his position from the
end of this month.
Avexa’s shares have plummeted
by 75% to just three cents.
The company has appointed a
corporate advisory firm to conduct
a strategic review “with the primary
focus of uncovering a transaction
that will be value accretive for our
shareholders,” said chairman
Nathan Drona.The above article was sent to subscribers in Pharmacy Daily's issue from 11 May 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 11 May 10
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.